Franklin, Parlapiano, Turner & Welch’s Pfizer PFE Stock Holding History

Franklin, Parlapiano, Turner & Welch’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,654	Closed	-$238K	–	50
2022 Q4	$238K	Hold	4,654	–	–	0.08%	45
2022 Q3	$204K	Hold	4,654	–	–	0.07%	46
2022 Q2	$244K	Hold	4,654	–	–	0.08%	45
2022 Q1	$241K	Hold	4,654	–	–	0.07%	48
2021 Q4	$275K	Hold	4,654	–	–	0.08%	46
2021 Q3	$200K	Buy	+4,654	New	+$206K	0.06%	50
2017 Q2	–	Sell	-3,721	Closed	-$121K	–	92
2017 Q1	$121K	Hold	3,721	–	–	0.06%	55
2016 Q4	$115K	Buy	3,721 +106	+3%	+$3.24K	0.06%	56
2016 Q3	$116K	Buy	+3,615	New	+$121K	0.06%	55
2016 Q1	–	Sell	-2,635	Closed	-$81K	–	130
2015 Q4	$81K	Hold	2,635	–	–	0.05%	61
2015 Q3	$79K	Buy	+2,635	New	+$84.5K	0.05%	58

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin, Parlapiano, Turner & Welch's PFE Position: Q1 2023 in Review

Franklin, Parlapiano, Turner & Welch sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,654 shares — an estimated $238K sold.

Franklin, Parlapiano, Turner & Welch first reported a position in PFE in Q3 2015 and held it in 11 quarters. The position peaked at $275K in Q4 2021. 3,105 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

Franklin, Parlapiano, Turner & Welch reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
Franklin, Parlapiano, Turner & Welch sold 4,654 Pfizer shares in Q1 2023, an estimated $238K.
Franklin, Parlapiano, Turner & Welch first reported a position in Pfizer in Q3 2015 and held it in 11 quarters.
Franklin, Parlapiano, Turner & Welch's Pfizer position peaked at $275K in Q4 2021.
3,105 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Franklin, Parlapiano, Turner & Welch's 13F filing for Q1 2023, filed 2 May 2023.